Cancer chemotherapy in the elderly patient

ONCOLOGY

Volumn 24, Issue 1, 2010, Pages

  Gillison, Timothy L ^a   Chatta, Gurkamal S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUOROURACIL PLUS IRINOTECAN PLUS LEUCOVORIN; 5 FLUOROURACIL PLUS LEUCOVORIN; ALEMTUZUMAB; AROMATASE INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM; PREDNISONE; RITUXIMAB; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG DISTRIBUTION; DRUG METABOLISM; ELDERLY CARE; GLOMERULUS FILTRATION RATE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; PROSTATE CANCER; REVIEW;

EID: 76149131986     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Balducci L: Geriatric oncology. Crit Rev Oncol Hematol 46:211-220, 2003.
2. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
3. Yancik RP, Carbone PP, Patterson WB, et al (eds): Perspectives on Prevention and Treatment of Cancer in the Elderly. New York, Raven Press, 1983.
4. American Cancer Society: Cancer Facts & Figures 2009. Atlanta, American Cancer Society, 2009.
5. National Cancer Institute: SEER Cancer Statistics Review, 2002-2006, Tables1.10 and 1.12. Rockville, Md; National Cancer Institute; 2009.
6. Bernardi D, Errante D, Tirelli U, et al: Insight into the treatment of cancer in older patients: developments in the last decade. Cancer Treat Rev 32:277-288, 2006.
7. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389, 2003.
8. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007.
9. Hurria A., Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005.
10. Balducci L: Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 23:78-85, 2009.
11. Hurria A, Lichtman SM: Clinical pharmacology of cancer therapies in older adults. Br J Cancer 98:517-522, 2008.
12. Lichtman SM: Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol 5:181-182, 2007.
13. Lichtman SM, Wildiers H, Chatelut E, et al: International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patientsan analysis of the medical literature. J Clin Oncol 25:1832-1843, 2007.
14. Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34, 2007.
15. Bouchardy C, Rapiti E, Fioretta G, et al: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580-3587, 2003.
16. Hébert-Croteau N, Brisson J, Latreille J, et al: Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 85:1104-1113, 1999.
17. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002.
18. Belani C, Fossella F: Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: Analyses in elderly patients (abstract 2528). Proc Am Soc Clin Oncol 22:629, 2003.
19. Berardi R, Porfiri E, Scartozzi M, et al: Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine. Oncology 65:198-203, 2003.
20. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.
21. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536, 2000.
22. Ramalingam SS, Dahlberg SE, Langer CJ, et al: Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60-65, 2008.
23. Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323, 2007.
24. Fidias P, Supko JG, Martins R, et al: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7:3942-3949, 2001.
25. Garbo L, Marsland T, Garfield D, et al: A phase II study of weekly paclitaxel (Taxol) in stage IIIb, IV, or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or e 70 years (yrs) of age, with Paraplatin administered at disease progression (abstract 2821). Proc Am Soc Clin Oncol 20:267b, 2001.
26. Karampeazis A, Vamvakas L, Agelidou A, et al: Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial (abstract 7615). J Clin Oncol 25(18S), 2007.
27. West W, Birch R, Sysel I, et al: A phase II trial of weekly paclitaxel in eldery patients or those with decreased performance status with advanced non-small cell lung cancer (abstract 2782). Proc Am Soc Clin Oncol 20:258b, 2001.
28. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005.
29. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002.
30. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006.
31. Pirker R, Szczesna A, von Pawel J, et al: FLEX: A radomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) vesus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (abstract 3). J Clin Oncol 26(15S):6s, 2008.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
33. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003.
34. Kudoh S, Takeda K, Nakagawa K, et al: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657-3663, 2006.
35. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000.
36. Gennari R, Curigliano G, Rotmensz N, et al: Breast carcinoma in elderly women: Features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 101:1302-1310, 2004.
37. Singh R, Hellman S, Heimann R: The natural history of breast carcinoma in the elderly: Implications for screening and treatment. Cancer 100:1807-1813, 2004.
38. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
39. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
40. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
41. Kaufmann M, Jonat W, Hilfrich J, et al: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 25:2664-2670, 2007.
42. Thurlimann B, Keshaviah A, Coates AS, et al, for the Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
43. Carlson RW, Allred DC, Anderson BO, et al: Breast cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7(2):122-192, 2009.
44. Audisio RA, Bozzetti F, Gennari R, et al: The surgical management of elderly cancer patients: Recommendations of the SIOG surgical task force. Eur J Cancer 40:926-938, 2004.
45. Verkooijen HM, Fioretta GM, Rapiti E, et al: Patients refusal of surgery strongly impairs breast cancer survival. Ann Surg 242:276-280, 2005.
46. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006.
47. Elkin EB, Hurria A, Mitra N, et al: Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: Assessing outcome in a population-based, observational cohort. J Clin Oncol 24:2757-2764, 2006.
48. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009.
49. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005.
50. Fargeot P, Bonneterre J, Roché H, et al: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol 22:4622-4630, 2004.
51. Giordano S, Pinder M, Duan Z, et al: Congestive heart failure in older women treated with anthracycline (A) chemotherapy (C) (abstract 521). J Clin Oncol 24(18S), 2006.
52. Feher O, Vodvarka P, Jassem J, et al: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Ann Oncol 16:899-908, 2005.
53. Bajetta E, Procopio G, Celio L, et al: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23:2155-2161, 2005.
54. Mlineritsch B, Schabel-Moser R, Andel J, et al: Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 32:18-24, 2009.
55. Damber JE, Aus G: Prostate cancer. Lancet 371:1710-1721, 2008.
56. Barry MJ: Screening for prostate cancerthe controversy that refuses to die. N Engl J Med 360:1351-1354, 2009.
57. Centers for Disease Control and Prevention: Prostate Cancer Screening: A Decision Guide. Atlanta, US Dept of Health and Human Services, 2009.
58. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185-191, 2008.
59. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005.
60. Kotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005.
61. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596-1605, 2007.
62. Harle LK, Maggio M, Shahani S, et al: Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4:687-696, 2006.
63. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041, 2007.
64. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45, 2001.
65. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454, 2008.
66. Tannock IF, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
67. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005.
68. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007.
69. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005.
70. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
71. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097. 2001.
72. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 321:531-535, 2000.
73. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002.
74. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-2418, 1999.
75. Folprecht G, Rougier P, Slatz L, et al: Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan (abstract 3578). J Clin Oncol 24(18S):165s, 2006.
76. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006.
77. Daniele B, Rosati G, Tambaro R, et al: First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: A phase II study. J Clin Gastroenterol 36:228-233, 2003.
78. Feliu J, Salud A, Escudero P, et al: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94:969-975, 2006.
79. Sastre J, Marcuello E, Masutti B, et al: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23:3545-3551, 2005.
80. Souglakos J, Pallis A, Kakolyris S, et al: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 69:384-390, 2005.
81. Figer A, Perez N, Carola E, et al: 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer (abstract 3571). J Clin Oncol 22(14S), 2004.
82. Comandone A, Pochettino T, Bergnolo P, et al: Capecitabine and oxaliplatin: A phase II study with a new schedule of administrtion in elderly patients with advanced colorectacl cancer (abstract 3681). J Clin Oncol 23(16S), 2005.
83. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006.
84. Rossi DJ, Bryder D, Zahn JM, et al: Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102:9194-9199, 2005.
85. Estey EH: General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol 43:89-95, 2006.
86. Estey EH: Older adults: Should the paradigm shift from standard therapy? Best Pract Res Clin Haematol 21:61-66, 2008.
87. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001.
88. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329, 1997.
89. Tilly H, Castaigne S, Bordessoule D, et al: Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279, 1990.
90. ODonnell MR, Applebaum FR, Coutre SE, et al: Acute myeloid leukemia. J Natl Compr Canc Netw 6:962-993, 2008.
91. Estey E: Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25:1908-1915, 2007.
92. Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 371:1017-1029, 2008.
93. Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: Emphasis on risk factors for progression. Br J Haematol 139:730-743, 2007.
94. Kyle RA, Rajkumar SV: Multiple myeloma. Blood 111:2962-2972, 2008.
95. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
96. Westin EH, Longo DL: Lymphoma and myeloma in older patients. Semin Oncol 31:198-205, 2004.
97. Zelenetz AD, Advani RH, Byrd JC, et al: Non-Hodgkins lymphomas. J Natl Compr Canc Netw 6:356-421, 2008.
98. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkins lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004.
99. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkins lymphoma. J Clin Oncol 13:2386-2393, 1995.
100. Jabbour E, Chalhoub B, Suzan F, et al: Outcome of elderly patients with aggressive Non-Hodgkins lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure. Leuk Lymphoma 45:1391-1394, 2004.
101. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe dEtude des Lymphomes de lAdulte. J Clin Oncol 23:4117-4126, 2005.
102. Jantunen E: Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 38:715-720, 2006.
103. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-205, 2006.